Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway

Outcomes have not improved for metastatic osteosarcoma for several decades. In part, this failure to develop better therapies stems from a lack of understanding of osteosarcoma biology, given the rarity of the disease and the high genetic heterogeneity at the time of diagnosis. We report here the su...

Descripción completa

Detalles Bibliográficos
Autores principales: VanCleave, Ashley, Palmer, Mykayla, Fang, Fang, Torres, Haydee, Rodezno, Tania, Li, Qilin, Fuglsby, Kirby, Evans, Claire, Afeworki, Yohannes, Ross, Alan, Rao, Pulivarthi, Leiferman, Patricia, Zheng, Siyuan, Houghton, Peter, Tao, Jianning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343631/
https://www.ncbi.nlm.nih.gov/pubmed/32676162
http://dx.doi.org/10.18632/oncotarget.27611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343631/
https://www.ncbi.nlm.nih.gov/pubmed/32676162
http://dx.doi.org/10.18632/oncotarget.27611

Ejemplares similares